Add to ORKGAbstract The results of recent clinical trials have demon-strated that cancer vaccines continue to struggle to achieve tangible clinical beneWts as monotherapy. Tumor-induced abnormalities in the immune system hamper anti-tumor T cell responses limiting the eVectiveness of cancer immunotherapy. Recently, evidence has been mounting to suggest that immunotherapy has the possibility of achieving better success when used in combination with conventional chemotherapy. In clinical trials, immune responses elicited by cancer vaccines appear to augment the eVectiveness of subsequent conventional cancer therapies
Monoclonal antibodies (mAbs) have just turned into an essential piece of the treatment for various c...
To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial ...
The immune system plays a vital role in regulating the growth of tumors. Some types of inflammatory ...
Our insight into antitumour immune responses has increased considerably during the past decades, yet...
Because of the failure of immunotherapy as single agent in a number of cancers, current clinical tri...
The clinical efficacy of most therapeutic vaccines against cancer has not yet met its promise. Data ...
Because of the failure of immunotherapy as single agent in a number of cancers, current clinical tri...
Although cancer chemotherapy has historically been con-sidered immune suppressive, it is now accepte...
Although cancer chemotherapy has historically been considered immune suppressive, it is now accepted...
Clinical responses to immunotherapy can be complete and sustained; however, compared to responses t...
IntroductionBreakthroughs in cancer immunotherapy have spurred interest in the development of vaccin...
During the recent years, new information obtained from basic immunology and from the use of molecula...
Using the immune system to control cancer has been investigated for over a century. Yet it is only o...
Not until the turn of this century has immunotherapy become a fundamental component of cancer treatm...
Cancer can coaptate the immune control of the immune system (IS), evade immunity and its destruction...
Monoclonal antibodies (mAbs) have just turned into an essential piece of the treatment for various c...
To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial ...
The immune system plays a vital role in regulating the growth of tumors. Some types of inflammatory ...
Our insight into antitumour immune responses has increased considerably during the past decades, yet...
Because of the failure of immunotherapy as single agent in a number of cancers, current clinical tri...
The clinical efficacy of most therapeutic vaccines against cancer has not yet met its promise. Data ...
Because of the failure of immunotherapy as single agent in a number of cancers, current clinical tri...
Although cancer chemotherapy has historically been con-sidered immune suppressive, it is now accepte...
Although cancer chemotherapy has historically been considered immune suppressive, it is now accepted...
Clinical responses to immunotherapy can be complete and sustained; however, compared to responses t...
IntroductionBreakthroughs in cancer immunotherapy have spurred interest in the development of vaccin...
During the recent years, new information obtained from basic immunology and from the use of molecula...
Using the immune system to control cancer has been investigated for over a century. Yet it is only o...
Not until the turn of this century has immunotherapy become a fundamental component of cancer treatm...
Cancer can coaptate the immune control of the immune system (IS), evade immunity and its destruction...
Monoclonal antibodies (mAbs) have just turned into an essential piece of the treatment for various c...
To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial ...
The immune system plays a vital role in regulating the growth of tumors. Some types of inflammatory ...